Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics
- 19 April 2015
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 170 (3) , 305-322
Abstract
Summary: The acute myeloid leukaemia (AML) genome contains more than 20 driver recurrent mutations. Here, we review the potential for therapeutic targeting of the most common mutations associated with normal cytogenetics AML, focusing on those affecting the FLT3, NPM1 and epigenetic modifier genes (DNMT3A, IDH1/2, TET2). As compared to early compounds, second generation FLT3 inhibitors are more specific and have better pharmacokinetics. They also show higher anti‐leukaemic activity, leading to about 50% of composite complete remissions in refractory/relapsed FLT3‐internal tandem duplication‐mutated AML. However, rapid relapses invariably occur due to various mechanisms of resistance to FLT3 inhibitors. This issue and the best way for using FLT3 inhibitors in combination with other therapeutic modalities are discussed. Potential approaches for therapeutic targeting of NPM1‐mutated AML include: (i) reverting the aberrant nuclear export of NPM1 mutant using exportin‐1 inhibitors; (ii) disruption of the nucleolus with drugs blocking the oligomerization of wild‐type nucleophosmin or inducing nucleolar stress; and (iii) immunotherapeutic targeting of highly expressed CD33 and IL3RA (CD123) antigens. Finally, we discuss the role of demethylating agents (decitabine and azacitidine) and IDH1/2 inhibitors in the treatment of AML patients carrying mutations of genes (DNMT3A, IDH1/2 and TET2) involved in the epigenetic regulation of transcription.Keywords
Funding Information
- AIRC (Associazione Italiana Per La Ricerca Sul Cancro) (IG 2013 N.14595)
This publication has 160 references indexed in Scilit:
- A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in miceLeukemia, 2013
- Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesisNature Genetics, 2012
- Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patternsLeukemia, 2012
- A potential therapeutic target for FLT3-ITD AML: PIM1 kinaseLeukemia Research, 2012
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- Recurrent DNMT3A mutations in patients with myelodysplastic syndromesLeukemia, 2011
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-HydroxyglutarateCancer Cell, 2010
- DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid LeukemiaCancer Cell, 2010
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009